Pharmamel

Pharmamel is a clinical-stage biotech developing novel melatonin-based therapeutics for severe inflammatory and oxidative conditions. Its lead program targets sepsis, a life-threatening immune response to infection, and it holds a robust international patent portfolio covering formulations for sepsis, viral diseases, cancer, and mucositis. The company is currently in a pre-IPO phase, actively raising capital through a regulated platform to finance clinical development and pursue a public listing on the Spanish BME Scaleup market.

Proprietary formulation and repurposing platform for high-dose melatonin, focusing on specific effective concentration ranges and delivery methods (injectable, topical) to exploit its potent antioxidant and anti-inflammatory properties for severe medical conditions.

Competition in sepsis is intense but focused on novel molecules; Pharmamel's repurposed, formulation-based approach is unique. In mucositis, it would compete with existing palliative care products. Its key defense is a strong international patent portfolio on specific melatonin formulations and concentrations.